JERUSALEM, Nov. 1, 2011 (GLOBE NEWSWIRE) -- Further to that stated in Brainsway's (TASE:BRIN) periodic report for 2010, the Company is pleased to announce that it has received an Investigational Device Exemption ("IDE") approval from the U.S. Food and Drug Administration ("FDA"), allowing it to begin a multicenter clinical trial to evaluate the efficacy of its Deep TMS device in the treatment of subjects with bipolar disorder. The IDE was granted in respect of nine medical centers and 120 patients.
